A framework for assessment of adverse events occurring in psychedelic-assisted therapies.

IF 4.5 3区 医学 Q1 CLINICAL NEUROLOGY Journal of Psychopharmacology Pub Date : 2024-08-01 Epub Date: 2024-07-31 DOI:10.1177/02698811241265756
Roman Palitsky, Deanna M Kaplan, John Perna, Zachary Bosshardt, Jessica L Maples-Keller, Holly F Levin-Aspenson, Ali John Zarrabi, Caroline Peacock, Tanja Mletzko, Barbara O Rothbaum, Charles L Raison, George H Grant, Boadie W Dunlop
{"title":"A framework for assessment of adverse events occurring in psychedelic-assisted therapies.","authors":"Roman Palitsky, Deanna M Kaplan, John Perna, Zachary Bosshardt, Jessica L Maples-Keller, Holly F Levin-Aspenson, Ali John Zarrabi, Caroline Peacock, Tanja Mletzko, Barbara O Rothbaum, Charles L Raison, George H Grant, Boadie W Dunlop","doi":"10.1177/02698811241265756","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Despite considerable research examining the efficacy of psychedelic-assisted therapies (PATs) for treating psychiatric disorders, assessment of adverse events (AEs) in PAT research has lagged. Current AE reporting standards in PAT trials are poorly calibrated to features of PAT that distinguish it from other treatments, leaving many potential AEs unassessed.</p><p><strong>Methods: </strong>A multidisciplinary working group of experts involved in PAT pooled formally and informally documented AEs observed through research experience and published literature. This information was integrated with (a) current standards and practices for AE reporting in pharmacotherapy and psychotherapy trials and (b) published findings documenting post-acute dosing impacts of psychedelics on subjective states, meaning, and psychosocial health variables, to produce a set of AE constructs important to evaluate in PAT as well as recommended methods and time frames for their assessment and monitoring. Correspondence between identified potential AEs and current standards for AE assessment was examined, including the extent of coverage of identified AE constructs by 25 existing measures used in relevant research.</p><p><strong>Results: </strong>Fifty-four potential AE terms warranting systematized assessment in PAT were identified, defined, and categorized. Existing measures demonstrated substantial gaps in their coverage of identified AE constructs. Recommendations were developed for how to assess PAT AEs (including patient, clinician, and informant reports), and when to assess over preparation, dosing session, integration, and follow-up. Application of this framework is demonstrated in a preliminary assessment protocol (available in the supplement).</p><p><strong>Conclusions: </strong>This assessment framework addresses the need to capture post-acute dosing AEs in PAT, accounting for its pharmacotherapy and psychotherapy components, as well as documented impacts of psychedelics on worldviews and spirituality.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"690-700"},"PeriodicalIF":4.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02698811241265756","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/31 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Despite considerable research examining the efficacy of psychedelic-assisted therapies (PATs) for treating psychiatric disorders, assessment of adverse events (AEs) in PAT research has lagged. Current AE reporting standards in PAT trials are poorly calibrated to features of PAT that distinguish it from other treatments, leaving many potential AEs unassessed.

Methods: A multidisciplinary working group of experts involved in PAT pooled formally and informally documented AEs observed through research experience and published literature. This information was integrated with (a) current standards and practices for AE reporting in pharmacotherapy and psychotherapy trials and (b) published findings documenting post-acute dosing impacts of psychedelics on subjective states, meaning, and psychosocial health variables, to produce a set of AE constructs important to evaluate in PAT as well as recommended methods and time frames for their assessment and monitoring. Correspondence between identified potential AEs and current standards for AE assessment was examined, including the extent of coverage of identified AE constructs by 25 existing measures used in relevant research.

Results: Fifty-four potential AE terms warranting systematized assessment in PAT were identified, defined, and categorized. Existing measures demonstrated substantial gaps in their coverage of identified AE constructs. Recommendations were developed for how to assess PAT AEs (including patient, clinician, and informant reports), and when to assess over preparation, dosing session, integration, and follow-up. Application of this framework is demonstrated in a preliminary assessment protocol (available in the supplement).

Conclusions: This assessment framework addresses the need to capture post-acute dosing AEs in PAT, accounting for its pharmacotherapy and psychotherapy components, as well as documented impacts of psychedelics on worldviews and spirituality.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
迷幻辅助疗法不良事件评估框架。
目的:尽管对迷幻辅助疗法(PATs)治疗精神障碍的疗效进行了大量研究,但对PAT研究中的不良事件(AEs)的评估却一直滞后。目前PAT试验中的不良事件报告标准与PAT区别于其他疗法的特点不符,导致许多潜在的不良事件未得到评估:方法:由参与 PAT 的多学科专家组成的工作组汇集了通过研究经验和已发表文献观察到的正式和非正式记录的 AE。这些信息与(a)药物治疗和心理治疗试验中AE报告的现行标准和实践,以及(b)已发表的记录迷幻剂急性用药后对主观状态、意义和社会心理健康变量影响的研究结果相结合,形成了一套在PAT中需要评估的AE结构,以及对其评估和监测的建议方法和时间框架。研究人员检查了已确定的潜在 AE 与当前 AE 评估标准之间的对应关系,包括相关研究中使用的 25 种现有测量方法对已确定的 AE 结构的覆盖程度:结果:确定、定义和分类了 54 个需要在 PAT 中进行系统评估的潜在 AE 术语。现有测量方法在涵盖已识别的 AE 构建方面存在很大差距。针对如何评估 PAT AE(包括患者、临床医生和信息提供者的报告)以及何时评估准备、用药疗程、整合和随访提出了建议。该框架的应用在初步评估方案中进行了演示(见补充资料):这一评估框架满足了捕捉PAT急性用药后AEs的需要,考虑到了其药物治疗和心理治疗的成分,以及有文献记载的迷幻剂对世界观和灵性的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Psychopharmacology
Journal of Psychopharmacology 医学-精神病学
CiteScore
8.60
自引率
4.90%
发文量
126
审稿时长
3-8 weeks
期刊介绍: The Journal of Psychopharmacology is a fully peer-reviewed, international journal that publishes original research and review articles on preclinical and clinical aspects of psychopharmacology. The journal provides an essential forum for researchers and practicing clinicians on the effects of drugs on animal and human behavior, and the mechanisms underlying these effects. The Journal of Psychopharmacology is truly international in scope and readership.
期刊最新文献
High-dose Vitamin-B6 reduces sensory over-responsivity. Clinical effects of CYP2D6 phenoconversion in patients with psychosis. Influence of panic disorder and paroxetine on brain functional hubs in drug-free patients. Aspirin may be more suitable for patients with major depression: Evidence from two-sample Mendelian randomization analysis. Optimizing the individual dosing of paroxetine in major depressive disorder with therapeutic drug monitoring.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1